Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-C9074 in Advanced Solid Tumors
NCT06233942Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BG-C9074 in solid tumor (7 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 3 years, Maximum Tolerated Dose or Maximum Administered Dose at 18 months and 3 more. Started Apr 2024; status: recruiting.
02
Drugs
BG-C9074
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06233942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233942.